Digital pathology Market Size was valued at USD 1.21 Billion in 2023. The Global Digital pathology industry is projected to grow from USD 1.31 Billion in 2024 to USD 2.23 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.11% during the forecast period (2024 - 2032).The rise in the incidence of cancer, the desire for precise diagnoses, and the development of innovative digital pathology systems by a significant number of important players are the main market drivers of the growth.
In October 2023, Pramana and Gestalt announced a single, unified offering that combines digital pathology, AI, image analysis, and DICOM into an integrated AI-powered platform and digital pathology solutions.
In August 2023, PathAI introduced AISight Digital Pathology Image Management System for the future of the pathology lab. AISight is a cloud-based platform that harmonizes digital pathology workflow through advanced image and case management as well as viewing ingestion and seamless integration of AI applications. AISight is a cloud-based platform that harmonizes digital pathology workflow through advanced image and case management as well as viewing ingestion and seamless integration of AI applications.
In March 2023, Ibex (Ibex Medical Analytics) was awarded a PathLAKE contract to deliver AI-enabled offerings in 25 NHS sites to aid cancer diagnosis.
In March 2023, PathAI introduced AISight across the U.S. leading health systems: reference laboratories, medical centers or independent pathology organizations involved in the Early Access Program.
In March 2023, Qritive entered into a partnership with Corista to integrate the company’s DP3 – DICOM-compliant pathology software into digital pathology using AI technology.
For example, in February 2023, Fujifilm acquired Inspirata global business on digital pathology, including its Dynamyx system for digital histopathology,
In November 2022, University Medical Center Utrecht partnered with Paige to bring its application into clinical use and conduct a clinical health economics study supporting reimbursement and adoption of AI applications in pathologies.
The DIFF-Line technology was launched at the AACC Convention in Chicago, USA, by CellaVision to cater specifically to low-volume hematology labs. These comprise three instruments; CellaVision DC-1, RAL SmearBox, and RAL StainBox, used for smearing staining/and analyzing peripheral blood smears. This technology became available on European markets by July 2022, and plans are in place to expand to other regions before the end of the year.
In June 2022, F. Hoffmann-La Roche Ltd. was awarded a CE Mark for its next-generation high-capacity slide scanner called VENTANA DP 600 Slide Scanner, that produces high-resolution digital images of stained tissue samples useful in cancer diagnosis and treatment planning.
For example, in April 2022, PreciseDx teamed up with Michael J. Fox Foundation for the launch of AI-backed digital pathology technology for early diagnosis of Parkinson's disease patients.
For instance, in January 2022, Inform Diagnostics deployed FullFocus, a digital pathology viewer from Paige that would allow their laboratory work to apply AI tools, which will help streamline logistics, leading faster results obtained by them.
Chronic diseases like cancer, diabetes, and cardiovascular diseases, which account for USD 4.1 trillion of the country's yearly healthcare costs, are major causes of disability and death in the United States, according to the Centers for Disease Control and Prevention. In the U.S., six out of ten adults as of July 2022 have a chronic illness, and four out of ten have two or more. According to figures released by the WHO, one in six persons worldwide is predicted to be older than 60 by the year 2030. The number of people 60 and older worldwide is predicted to reach approximately 2.1 billion by 2050. Additionally, between 2020 and 2050, there will be 426 million people who are 80 years of age or older. The aged population has a higher prevalence of chronic diseases. Thus, it is anticipated that an aging population would lead to an increase in chronic diseases such as cancer, and that demand will fuel the expansion of the digital pathology industry. Thus, this factor is driving the market CAGR.
Furthermore, the utilization of cutting-edge hardware and software has expanded due to a paradigm shift towards the creation of advanced infrastructure for the provision of effective healthcare services. Utilizing networked data-sharing capabilities, such cutting-edge systems can employ big data in healthcare to automate data management, support decision-making, and offer effective data analysis services. The demand for tele-consultation services has increased due to the rising interest of governments of emerging economies in promoting mobile health (mHealth) services as a complementary method to meet the health-related Millennium Development Goal. In order to provide effective healthcare services, the expanding IoT infrastructure development makes it simple to integrate digital pathology systems in laboratories. The market will grow significantly as a result of this.
However, through connected systems, the employment of smarter and more interoperable laboratory technology has been made possible by the advent of IoT in pathology laboratory services as part of the digitization of healthcare. The growth of big healthcare data is mostly being driven by digital pathology data. One laboratory facility, for instance, generates between 1 and 1.5 PB of data annually utilizing a digital pathology system. Concerns about the storage of data gathered by linked equipment have also been allayed by the lower cost of cloud-based storage services. Between 2015 and 2030, it is anticipated that the cost of keeping laboratory data would drop by around 98.98%. This is expected to reduce the additional cost involved in the storage of digital pathology data to some extent, making it more accessible to end-users. Thus, it is anticipated that this aspect will accelerate digital pathology market revenue globally.
The Digital Pathology Market segmentation, based on type, includes Human Pathology and Animal Pathology. The human pathology segment held the majority share in 2022 in the Digital Pathology Market data. The use of digital pathology enables more precise analysis. It contains quick, accurate, and objective automatic slide analysis techniques. Additionally, it provides quick access to previously connected instances for scientists, stores data for long-term predictive analytics, and aids in the quicker and more precise detection of serious illnesses like tumours by doctors.
Figure 2: Digital Pathology Market, by Type, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Digital Pathology Market segmentation, based on product, includes hardware, software and storage. The hardware segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. The rise in in-vitro testing facilities and the requirement for quicker results are to blame for the rising demand for hardware items, which is expected to propel the segment's expansion.
The global digital pathology industry, based on application, includes telemedicine, drug discovery, disease diagnosis and mhealth. The drug discovery segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032 due to rising need for prospective pipeline medications to treat serious illnesses as well as new uses for pathology techniques in drug discovery, like high-throughput screening.
The Digital Pathology Market data, based on end user, includes Hospitals & Clinics, Research Centers & Academic Institutes and Diagnostic Centers. The hospitals & clinics segment dominated the digital pathology market revenue for digital pathology in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. The segment's dominance is related to the rise in hospital admissions and pathology services provided by large hospitals. The segment is also expected to rise as a result of strategic agreements with leading hospitals to deliver cutting-edge technologies and more usage of digital tools because of increased foot traffic.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America digital pathology market accounted for USD 0.5 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. The market in this area is primarily driven by ongoing deployment of R&D investments, supportive government efforts pertaining to the development of technologically advanced systems, increased acceptance of digital imaging, and the presence of large competitors.
Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: DIGITAL PATHOLOGY MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Asia Pacific digital pathology market accounts for the second-largest market share. The expansion can be linked to investments in the medical sector, the presence of untapped prospects in the Asia Pacific, and the increased adoption of digital imaging in emerging nations. Due to the rising incidence of cancer, which affects a significant portion of the population, the healthcare sector in the Asia Pacific has had a significant impact on the market. Moreover, China digital pathology market held the largest market share, and the India digital pathology market was the fastest growing market in the region.
Europe digital pathology Market is expected to grow at the fastest CAGR from 2024 to 2032. The market is growing as more patients are choosing digital tools over traditional pathology and as important industry players in the area make strategic advancements such patenting unique technology. Further, the UK digital pathology market held the largest market share, and the Germany digital pathology market was the fastest growing market in the region.
Digital Pathology Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the digital pathology market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the digital pathology industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the global digital pathology industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, digital pathology industry has provided medicine with some of the most significant benefits. The digital pathology market major player such as Olympus Corporation (Japan), Danaher Corporation (Leica Biosystems GmbH) (U.S.), Inspirata (U.S.), 3DHISTECH Ltd. (Hungary), Huron Digital Pathology Inc. (Canada), Koninklijke Philips N.V. (The Netherlands), Hoffmann-La Roche Ltd. (Switzerland), microdimensions GmbH (Germany), Definiens (Germany), and Mikroscan Technologies, Inc. (U.S.).
The healthcare multinational F. Hoffmann-La Roche AG, also known as Roche, has two business segments that operate globally: pharmaceuticals and diagnostics. Shares of its parent firm, Roche Holding AG, are traded on the SIX Swiss Exchange. Basel is home to the corporate headquarters. In June 2022, Roche announced the release of the VENTANA DP 600 CE-certified slide scanner. While providing the pathology lab with user-friendliness and workflow flexibility, this high-capacity slide scanner creates high-quality photographs of stained histology slides from patient tissue samples.
The Dutch international conglomerate firm known simply as Philips was established in Eindhoven in 1891 as Koninklijke Philips N.V. The majority of its operations have been based in Amsterdam since 1997, however the Benelux headquarters remain in Eindhoven. In September 2021, In order to install multisite digital solutions for automating workflow, Koninklijke Philips N.V. announced its collaboration with Healius Pathology, an Australian provider of laboratory and pathology services. The project is designed to help the professionals at Healius Pathology make quick choices regarding patient care.
Key Companies in the digital pathology market includes
Digital Pathology Industry Developments
April 2022: In order to implement digital pathology tools throughout a network of 8 institutions, over 168 pathologists, and more than 1 million slides annually as part of its DigiPatICS initiative, 3DHISTECH Ltd. recently signed an agreement with the Catalan Health Institute (ICS). With a primary focus on establishing its market presence, the development enhances the company's reputation as a leading brand in the sector.
March 2022: The CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer is an automated next-generation sequencing (NGS) platform that can be used in clinical laboratories to conduct both diagnostic and clinical research. It was released by Thermo Fisher Scientific, Inc.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 1.21 billion |
| Market Size 2024 | USD 1.31 billion |
| Market Size 2032 | USD 1.23 billion |
| Compound Annual Growth Rate (CAGR) | 6.11% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Product, Application, End User and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Olympus Corporation (Japan), Danaher Corporation (Leica Biosystems GmbH) (U.S.), Inspirata (U.S.), 3DHISTECH Ltd. (Hungary), Huron Digital Pathology Inc. (Canada), Mikroscan Technologies, Inc. (U.S.) |
| Key Market Opportunities | The development of affordable scanners is expected to offer growth opportunities |
| Key Market Dynamics | Increasing prevalence of chronic conditions Technological improvements in software for image analysis |
Digital Pathology Market Highlights:
Frequently Asked Questions (FAQ) :
The Digital Pathology Market size was valued at USD 1.21 Billion in 2023.
The Digital Pathology Market is projected to grow at a CAGR of 6.11% during the forecast period, 2024-2032.
North America had the largest share in the global market for digital pathology.
The key players in the market are Olympus Corporation (Japan), Danaher Corporation (Leica Biosystems GmbH) (U.S.), Inspirata (U.S.), 3DHISTECH Ltd. (Hungary), Huron Digital Pathology Inc. (Canada), Mikroscan Technologies, Inc. (U.S.).
The human pathology dominated the market in 2023.
The hospitals & clinics had the largest share in the global market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
